slides · global inventory
Disclaimer
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 41,127
Current window 31,771-31,800
Pages 1,371
Rows per page 30
Component
31,771-31,800 of 41,127
10
The chart highlights NYCB's consistently lower non-performing loan ratios compared to the industry benchmark.New York Community Bancorp | Results Presentation Deck | 32 slides · New York Community Bancorp
Conference presentation Investor relations Beat · KPI OverviewLoop · Zoom In1 hit
11
NYCB is highlighted in gold; peer median is represented by a dashed line.New York Community Bancorp | Results Presentation Deck | 32 slides · New York Community Bancorp
Conference presentation Investor relations Beat · KPI OverviewLoop · Zoom In1 hit
20
Includes a dual-axis line chart for housing supply, a choropleth map for footprint, and a stacked bar chart for loan commitments.New York Community Bancorp | Results Presentation Deck | 32 slides · New York Community Bancorp
Conference presentation Investor relations Beat · Executive SummaryLoop · Golden Circle1 hit
02
Nexters | Investor Presentation Deck | 18 slidesNexters | Investor Presentation Deck | 18 slides · GDEV
Pitch deck Investor relations 1 hit
02
Nuvalent | Investor Presentation Deck | 52 slidesNuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations 1 hit
11
The table uses a green/white color coding to highlight positive attributes of NVL-520 compared to competitors.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
15
The slide uses a side-by-side comparison framework to delineate the two phases of the clinical trial.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · TractionLoop · Hypothesis Test1 hit
19
The chart displays dose-dependent exposure over 24 hours, with horizontal dashed lines representing efficacy targets for different ROS1 variants in CNS and periphery.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · TractionLoop · Hypothesis Test1 hit
20
Clinical trial data table showing efficacy metrics for NVL-520.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · TractionLoop · Hypothesis Test1 hit
21
Clinical trial data visualization (waterfall plot) with patient-level characteristics table below.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
22
Swimmer plot showing patient-level treatment duration, response status, and ongoing treatment status.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
23
Includes a spider plot (target lesion change) and a bar chart (allele clearance).Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
24
Includes patient case study with longitudinal MRI scans.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
25
The slide uses a timeline-style list on the left to show treatment history and a visual 'before-and-after' comparison of medical imaging on the right.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
26
Slide 26 of a pitch deck.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
27
Includes clinical trial data cut-offs and patient enrollment numbers.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
31
The table uses a green/white color coding to indicate positive vs negative results for specific ALK-related activities.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
36
Clinical trial baseline characteristics table.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
37
Data cut-off: 8 Aug 2023. Includes specific footnotes regarding dose modifications and discontinuations.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
39
The chart displays patient-level data categorized by dose (15mg to 200mg) and mutation type, highlighting the efficacy of the drug in clearing specific ALK mutations.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
40
The slide presents clinical trial data for NVL-655, showing efficacy across different resistance mutation profiles and prior treatment histories.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
41
Clinical trial data visualization showing ORR and best percentage change in target lesions.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
42
The chart is a swimmer plot, a standard visualization in oncology clinical trials to show time-to-event data for individual patients.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
43
Includes two patient case studies with MRI scans showing tumor reduction.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
47
The slide uses three distinct chart types to demonstrate the drug's competitive advantage in a preclinical setting.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations 1 hit
12
The slide uses a grouped bar chart to compare financial positions over time.Omnicell | Investor Presentation Deck | 27 slides · Omnicell
Conference presentation Investor relations Beat · Financials1 hit
13
Includes footnotes defining backlog and long-term backlog criteria.Omnicell | Investor Presentation Deck | 27 slides · Omnicell
Conference presentation Investor relations Beat · Financials1 hit
15
Omnicell | Investor Presentation Deck | 27 slidesOmnicell | Investor Presentation Deck | 27 slides · Omnicell
Conference presentation Investor relations Beat · Financials1 hit
19
Omnicell | Investor Presentation Deck | 27 slidesOmnicell | Investor Presentation Deck | 27 slides · Omnicell
Conference presentation Investor relations 1 hit
24
Includes footnotes (a) through (d) explaining specific adjustments and tax calculations.Omnicell | Investor Presentation Deck | 27 slides · Omnicell
Conference presentation Investor relations 1 hit